Abstract: The present disclosure belongs to the field of stem cell technology. Specifically, the present disclosure relates to a lyophilized powder of mesenchymal stem cells. More specifically, the present disclosure relates to a lyophilized adipose tissue derived mesenchymal stem cells. The present disclosure also relates to the advantageous use of lyophilized mesenchymal stem cells for long-term preservation, easy transportation and distribution of samples in a cost-effective way.

Abstract: The present invention relates to a topical dressing composition for the treatment of damaged skin tissue in a subject, wherein said topical dressing comprises mesenchymal stem cells embedded in a topical matrix. Particularly the invention relates to a storage-stable topical dressing composition for the treatment of damaged skin tissue in a subject, wherein said topical dressing comprises up to about 40,000 mesenchymal stem cells per square centimetre embedded in a topical matrix and, optionally a pharmaceutically acceptable excipient.

Abstract: The invention relates to a topical pharmaceutical composition for promoting hair growth and/or reducing hair loss in a human. In particular, the pharmaceutical composition comprises: (A) therapeutically effective amount of platelet component that includes a growth factor concentrate comprising platelet derived growth factor (PGDF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and transforming growth factor-? (TGF-?); and (B) a permeability enhancing agent.

Abstract: A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate.

Abstract: A once-a-day controlled release drug delivery system of diltiazem hydrochloride is provided, which is bioequivalent in plasma profile of Cardizem CD. The fast, medium, and slow release fractions are prepared using various compositions and weight gains. The individual fill weights are computed and then are filled into the same capsule using specialized encapsulation equipment using a triple-filling process. A preferred membrane dispersion that is used for preparing the fast release fraction contains 0.2% of sodium lauryl sulfate along with 20% of water soluble plasticizer (triethyl citrate), and 2% silicone dioxide, based on quaternary polymethacrylate on the weight basis. This combination provides an initial pulsatile burst after a lag time of 2 hours, leading to in-vivo bioequivalence. The preferred membrane dispersion that is used for preparing the medium release and the slow release fractions contain 16% of water soluble plasticizer along with 5% silicone dioxide, based on quaternary polymethacrylate.

Abstract: The present invention provides the components for a stable felodipine composition and a process for preparing the composition. The composition includes felodipine, non-covalently bound to &bgr;-cylodextrin, and an optional binder as a moisture carrier component for the migration of hydroxide ions to the non-covalently bound felodipine and &bgr;-cylodextrin. The felodipine composition is combined with a carrier comprising cyclodextrin particles, a water-insoluble alkaline component and a swellable polymer.

Abstract: The invention relates to the new arginine salt forms of S-(−)-9-fluoro-6,7-dihydro-8-(4-hydroxypiperidin-1-yl)-5-methyl-1-oxo-1H,5H-benzo[i,j]quinolizine-2-carboxylic acid, a process for their preparation and pharmaceutical formulations which comprise those arginine salt forms as the active ingredient for its use in treating antimicrobial infections.